Peficitinib

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Arthritis, Rheumatoid

Conditions

Arthritis, Rheumatoid

Trial Timeline

Jun 13, 2012 → Sep 30, 2019

NCT ID

NCT01638013

About Peficitinib

Peficitinib is a phase 3 stage product being developed by Astellas Pharma for Arthritis, Rheumatoid. The current trial status is completed. This product is registered under clinical trial identifier NCT01638013. Target conditions include Arthritis, Rheumatoid.

What happened to similar drugs?

20 of 20 similar drugs in Arthritis, Rheumatoid were approved

Approved (20) Terminated (0) Active (0)

✅NISEDr. Reddy's LaboratoriesApproved

✅Duloxetine + Sugar pillEli LillyApproved

✅Baricitinib + TNF InhibitorEli LillyApproved

✅Ixekizumab + AdalimumabEli LillyApproved

✅TacrolimusAstellas PharmaApproved

✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved

✅tacrolimus + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04143477	Phase 1	Completed	Dec 5, 2019	Dec 21, 2020	Healthy Volunteers
NCT03971253	Pre-clinical	Recruiting	Sep 2, 2019	May 31, 2026	Rheumatoid Arthritis (RA)
NCT02531191	Phase 1	Completed	Jun 21, 2015	Jul 15, 2015	Healthy Volunteers
NCT01711814	Phase 2	Completed	Sep 26, 2012	Mar 25, 2016	Arthritis, Rheumatoid
NCT01638013	Phase 3	Completed	Jun 13, 2012	Sep 30, 2019	Arthritis, Rheumatoid

Competing Products

20 competing products in Arthritis, Rheumatoid

See all competitors

Product	Company	Stage	Hype Score
DRL_RI + Rituxan + MabThera	Dr. Reddy's Laboratories	Phase 1/2	29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®	Dr. Reddy's Laboratories	Phase 3	37
NISE	Dr. Reddy's Laboratories	Approved	40
NISELAT	Dr. Reddy's Laboratories	Pre-clinical	23
Test Product + Reference product + Reference Medicinal Product	Dr. Reddy's Laboratories	Phase 1	22
Tocilizumab Prefilled Syringe	Dr. Reddy's Laboratories	Phase 1	26
Tilmanocept	Navidea Biopharmaceuticals	Phase 1	11
Tc99m tilmanocept	Navidea Biopharmaceuticals	Phase 2	25
KPL-404 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
LY2828360 + Placebo	Eli Lilly	Phase 2	35
Investigational Medical Product (IMP) administered in parent study	Eli Lilly	Phase 3	40
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo + Risankizumab	MoonLake Immunotherapeutics	Phase 3	41
Dose A VTX958 + Dose B VTX958 + Placebo	Ventyx Biosciences	Phase 2	21
LY2127399	Eli Lilly	Phase 3	32
Ixekizumab + Placebo	Eli Lilly	Phase 3	40